Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose‐finding trials

Phase 1 trials of molecularly targeted agents (MTA) often do not use toxicity data beyond the first cycle of treatment to determine a recommended phase 2 dose (RP2D). We investigated the potential utility of longitudinal relative dose intensity (RDI) that may be a better new way of determining a mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirakawa, Akihiro, Yonemori, Kan, Kinoshita, Fumie, Kobayashi, Yumiko, Okuma, Hitomi S., Kawachi, Asuka, Tamura, Kenji, Fujiwara, Yasuhiro, Rubinstein, Larry, Harris, Pamela Jo, Takebe, Naoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765308/
https://www.ncbi.nlm.nih.gov/pubmed/29114963
http://dx.doi.org/10.1111/cas.13436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765308/
https://www.ncbi.nlm.nih.gov/pubmed/29114963
http://dx.doi.org/10.1111/cas.13436

Ejemplares similares